Medical imaging: which AI startup is ahead?

Medical imaging AI has moved well beyond small hospital pilots. Several private companies now operate across thousands of healthcare sites, hold large regulatory portfolios and sit directly inside radiology or treatment workflows.

We compared the independent startups that analyze medical images and sell clinically deployed software. We focused on hospital adoption, regulatory progress, clinical evidence, commercial traction, workflow depth, international reach and recent momentum. Funding counted only when it had clearly produced stronger products, wider deployments or better customer access.

Which medical imaging AI startups are we actually comparing?

Seven private medical imaging AI startups belong in the main comparison today: Aidoc, Viz.ai, Qure.ai, RapidAI, Harrison.ai, AZmed and Avicenna.AI.

Each company directly analyzes scans and has moved beyond research into clinical use. Aidoc, Qure.ai and Harrison.ai are developing broader radiology systems. Viz.ai and RapidAI began with time-sensitive diseases such as stroke and are expanding into wider care pathways. AZmed concentrates on high-volume X-rays, while Avicenna.AI focuses on urgent and incidental CT findings.

We exclude companies that would distort the comparison. Lunit is publicly listed. Gleamer became part of RadNet’s DeepHealth after its acquisition. Deepc mainly provides the infrastructure through which hospitals deploy algorithms from several vendors. Rad AI is primarily a reporting and follow-up workflow company. Pathology, retinal imaging and highly specialized cardiac-imaging startups also sit outside this radiology-focused field.

Funding totals remain approximate because private-company databases treat debt, grants and secondary transactions differently. The differences are still large enough to show which companies have serious financial firepower.

Startup	Main medical imaging focus	Approximate cumulative funding	Why it belongs
Aidoc	Broad CT and X-ray analysis, triage, care coordination and report drafting	More than $500 million	The broadest private enterprise radiology AI platform
Viz.ai	Disease detection and coordination across imaging and clinical data	About $252 million	One of the largest hospital networks and the clearest profitability evidence
Harrison.ai	Comprehensive chest X-ray and CT interpretation	About $240 million	Broad second-reader technology with major NHS and Asia-Pacific deployments
Qure.ai	Chest X-ray, lung cancer, tuberculosis and neurocritical imaging	About $123 million	The widest international deployment network among the startups
RapidAI	Stroke, neurocritical, vascular and pulmonary imaging	About $100 million	The deepest specialist clinical evidence and a large hospital base
AZmed	Fracture, chest, bone-age and measurement tools for X-rays	About $22 million	An unusually capital-efficient X-ray specialist
Avicenna.AI	Emergency, vascular, trauma, spine and incidental CT findings	About $11 million	A small company with a substantial regulatory footprint

Is Aidoc already the clear leader in medical imaging AI?

Aidoc currently leads medical imaging AI overall, although Viz.ai remains close enough to prevent this from becoming a one-company race.

Aidoc now combines 31 FDA clearances, deployments in nearly 2,000 hospitals and more than $500 million in funding. Its latest progress is especially important because the company has moved from separate triage tools toward a foundation-model approach that can identify many acute findings from the same underlying system. Aidoc has also received a Breakthrough Device Designation for First Read, which analyzes chest X-rays and drafts preliminary report text for a radiologist to review.

Viz.ai has a similarly large hospital footprint and better financial evidence. The company says more than 2,000 hospitals use its platform, while its healthcare business became profitable during 2025. Its recent Agent Studio launch also lets health systems build their own AI-assisted care pathways instead of buying only fixed workflows designed by Viz.ai.

Qure.ai has moved closer to the top two lately. Its website now reports more than 5,500 sites across over 105 countries, 45 million lives reached and 26 FDA-cleared indications. RapidAI remains stronger in stroke evidence and reports more than 2,500 hospital deployments, but its recent growth and financial performance are less visible.

The result is one leader, one very close challenger and two strong companies immediately behind them. On a rough competitive index where Aidoc equals 100, Viz.ai sits around 91, Qure.ai around 84 and RapidAI around 81. The gaps become much larger after the top four.

If you want more recent data on this point, please see our latest healthcare AI market report.

Which startup has the strongest FDA portfolio in medical imaging AI?

Aidoc currently has the strongest proprietary FDA portfolio among broad medical imaging AI startups.

The company reports 31 FDA clearances, covering acute, vascular, abdominal, pulmonary, neurological and incidental findings. Its newer comprehensive product is particularly relevant because it received clearance for a double-digit group of acute indications powered by one foundation model. Aidoc says the system produces roughly ten times fewer false alerts than leading single-condition tools, although that comparison comes from the company and still needs broader independent replication.

Qure.ai is now the closest regulatory challenger. Six new clearances for its chest X-ray product took the company to 26 FDA-cleared indications. Qure.ai had only 19 cleared findings a few months earlier, so the recent increase represents a genuine acceleration.

Harrison.ai holds nine FDA clearances covering 13 radiological findings. Its international products can examine far more findings, but only a smaller part of that range currently carries American authorization.

Viz.ai promotes more than 50 FDA-cleared algorithms on its platform. That figure needs caution because a platform count can include several modalities and applications, and it does not always equal the number of separate regulatory submissions owned by the company.

Aidoc stays first on regulatory breadth, with Qure.ai closing the distance quickly.

Which medical imaging AI startup has the biggest and deepest deployment network?

Qure.ai has the widest reported site network, while RapidAI, Aidoc and Viz.ai appear stronger inside large hospital systems.

Qure.ai now reports more than 5,500 sites across over 105 countries. Earlier disclosures placed the company at more than 4,500 facilities during its 2024–25 financial year and around 4,800 later in 2025. The sequence suggests that Qure.ai added roughly 1,000 locations in little more than a year.

Those locations include hospitals, screening programs, mobile units and smaller health facilities. A Qure.ai screening site may therefore represent a lighter deployment than a full enterprise contract connecting imaging, alerts, specialists and treatment workflows.

RapidAI reports more than 2,500 hospitals in over 100 countries. Viz.ai and Aidoc each operate in roughly 2,000 hospitals. Aidoc also works across more than 150 health systems, while Viz.ai says its platform reaches a majority of the 50 largest American health systems.

Deployment depth changes the comparison. Aidoc can support several clinical applications through one technical layer. Viz.ai connects radiology findings with specialist alerts, transfer decisions and treatment pathways. RapidAI combines imaging analysis with stroke and vascular workflows that hospitals have used for years.

Harrison.ai has also made a serious move into national-scale deployment. Its software now operates across more than 58 NHS trusts and health boards covering over 150 hospitals. AZmed reports more than 2,500 healthcare facilities, mainly through lighter X-ray and radiology deployments.

Qure.ai leads on physical reach. RapidAI has the largest explicitly reported hospital count. Aidoc and Viz.ai appear strongest when the comparison shifts toward large, deeply integrated enterprise networks.

Startup	Latest reported scale	What the figure mainly represents	Current position
Qure.ai	5,500+ sites in 105+ countries	Hospitals, clinics, screening sites and public-health programs	Widest physical and geographic reach
RapidAI	2,500+ hospitals in 100+ countries	Acute-care and specialist hospital workflows	Largest clearly hospital-based footprint
AZmed	2,500+ healthcare facilities in 55+ countries	Predominantly radiology and X-ray locations	Exceptional scale for its funding
Viz.ai	2,000+ hospitals	Disease detection and care coordination	One of the deepest U.S. hospital networks
Aidoc	Nearly 2,000 hospitals	Enterprise radiology and clinical AI deployments	Strongest broad health-system presence
Harrison.ai	1,000+ customer sites	Hospitals, imaging networks and public systems	Major UK and Asia-Pacific position
Avicenna.AI	Regulatory access in 50+ countries	Precise current deployment count undisclosed	Broad authorization, smaller visible adoption

Which medical imaging AI startup has turned its technology into the strongest business?

Viz.ai currently has the clearest commercial lead because it has disclosed profitability alongside a network of more than 2,000 hospitals.

Viz.ai said its healthcare business became profitable during 2025. Its life-sciences business also doubled its partnerships over an 18-month period, giving the company another revenue source from pharmaceutical groups that want to find eligible patients and improve treatment pathways. Profitability is stronger evidence than a private valuation because it shows that customers are paying enough to support the operating business.

Aidoc may already generate more revenue, but the company has not published dependable revenue or profit figures. Its two consecutive $150 million rounds, large hospital footprint and participation from major health systems suggest considerable commercial demand. We still cannot tell how much recurring revenue each hospital produces or how close Aidoc is to profitability.

Qure.ai provides stronger operating evidence than most private rivals. During its 2024–25 financial year, its software reached more than 32 million people across 4,500 facilities. Its tuberculosis product screened more than seven million people during that year and flagged approximately 650,000 people as being at risk. The company has since expanded beyond 5,500 sites.

Capital efficiency changes the picture further. RapidAI built a 2,500-hospital footprint after raising around $100 million. AZmed reached more than 2,500 facilities after raising about $22 million. Avicenna.AI established regulatory access in more than 50 countries with only about $11 million in reported equity funding.

Harrison.ai remains the hardest business to judge. It has raised approximately $240 million, operates at more than 1,000 sites and is becoming part of NHS infrastructure, but it reveals little about realized software revenue or profitability.

Viz.ai leads commercially because it has paired hospital scale with profitability. Aidoc probably operates at greater financial scale, but reveals too little.

If you want more recent data on this point, please see our latest healthcare AI market report.

Which medical imaging AI startup is growing fastest now?

Aidoc currently has the strongest all-round momentum, while Qure.ai is expanding deployments and regulatory coverage at the fastest measurable pace.

Aidoc raised $150 million in one financing round and followed it with another $150 million less than a year later. During the same period, it secured clearance for a comprehensive foundation-model product and a Breakthrough Device Designation for preliminary report drafting. Capital, product scope and regulation are moving together, which makes Aidoc’s recent acceleration more substantial than a series of unrelated announcements.

Qure.ai has the cleanest numerical growth pattern. Its footprint rose from more than 4,500 facilities to more than 5,500, while its FDA-cleared indications increased from 19 to 26. It also received Gates Foundation support to develop point-of-care ultrasound AI for tuberculosis and childhood pneumonia.

Viz.ai is growing in a more financially disciplined way. It reached profitability in healthcare, passed 2,000 hospitals and launched Agent Studio. Its new pulmonary suite also expands the platform beyond the stroke and vascular workflows that originally built the company.

RapidAI added five FDA-cleared imaging modules in a single release, including products for medium-vessel occlusions, midline shift, hyperdensities and aortic measurements. It also announced 28 accepted scientific abstracts at a major stroke conference.

Harrison.ai could become the fastest-moving challenger. Harrison.Rad 1.5 can use images, clinical context and previous examinations to draft reports. The accompanying technical report says it was the only tested model to pass a simulated radiology board-exam standard. That remains a research result rather than proof of routine clinical adoption.

Aidoc has the momentum lead: financing, regulation, product scope and hospital adoption are all moving at once.

Which startup has the most mature medical imaging AI product?

RapidAI has the most mature specialist product, while Aidoc has the most mature broad radiology platform.

RapidAI has spent years building software around acute stroke decisions. Its products analyze non-contrast CT, CT angiography and perfusion imaging, while its workflow tools help specialists review cases and coordinate treatment. The company reports more than 700 clinical studies and over 2,500 hospital deployments.

Aidoc has reached greater maturity across multiple clinical areas. Its software can run continuously over hospital imaging, prioritize urgent examinations and connect findings with care coordination. The newer comprehensive foundation-model clearance should allow hospitals to cover several acute conditions through one system.

Viz.ai has built the most mature workflow after an abnormality is found. Its software alerts specialists, shares scans, organizes transfers and tracks cases through treatment.

Qure.ai is especially mature in public-health and lower-resource environments. Its tuberculosis program alone processed more than seven million screenings during one financial year.

A stroke center could reasonably place RapidAI first. A health system seeking one broad imaging AI platform would probably choose Aidoc.

Which medical imaging AI startup has the strongest clinical evidence?

RapidAI still has the deepest overall clinical evidence, with Qure.ai leading in large public-health programs and AZmed becoming a serious evidence-based challenger in X-ray.

RapidAI reports more than 700 clinical studies, including research connected to the expansion of stroke-treatment guidelines. The company also presented 28 abstracts at the latest International Stroke Conference. Some papers use RapidAI as a measurement or patient-selection tool rather than evaluating the complete commercial platform, but the overall research base remains much deeper than that of most competitors.

Qure.ai has built a broad evidence library across tuberculosis, lung cancer, stroke and chest imaging. Its 2024–25 impact report describes more than seven million tuberculosis screenings and more than five million people screened for lung cancer across 20 countries. Qure.ai’s evidence is valuable because it includes national programs and difficult real-world environments rather than only controlled hospital datasets.

Aidoc has credible workflow and diagnostic studies, although its public research total remains smaller than RapidAI’s. A randomized intracranial-hemorrhage study found that AI prioritization reduced average reporting time from 132 minutes to 73 minutes. Another quality-assurance study found fewer missed hemorrhages when radiologists received Aidoc alerts.

AZmed has recently strengthened its position. A large international evaluation covered more than 258,000 X-rays from 100 clinical centers across 26 countries. Another validation study covered 18 thoracic and musculoskeletal pathologies using more than 21,000 examinations from 52 centers in 20 countries.

Harrison.ai’s newest foundation-model research is technically ambitious, but much of the evidence still comes from company-led benchmarks and simulated examinations. Viz.ai has useful studies around reduced treatment delays and better coordination.

RapidAI still ranks first on clinical evidence because its research has accumulated over many years and connects directly with established stroke care.

If you want more recent data on this point, please see our latest healthcare AI market report.

Can any medical imaging AI startup prove that its algorithms are the most accurate?

No medical imaging AI startup can credibly claim the best accuracy across every scan type and disease.

The companies solve different problems. Detecting a brain hemorrhage on CT, finding a fracture on X-ray and screening for tuberculosis require different datasets, thresholds and clinical trade-offs. Comparing their published sensitivity or accuracy figures directly would create a false ranking.

Even within one disease, performance changes with the patient population, scanner, image quality and chosen threshold. Older patients, previous disease and unusual imaging protocols can all weaken performance.

Independent head-to-head evaluations offer the fairest evidence. One comparison of five commercial tuberculosis systems found that Qure.ai’s qXR achieved the highest area under the curve, at about 90.8%. The lead over the closest competitor was small, and every product performed worse in some patient groups.

AZmed’s recent study across 258,000 X-rays is useful because it spans 100 centers and 26 countries. The study’s size reduces the risk that performance reflects one hospital’s scanners or patient mix, although we still need more prospective evidence showing how the product changes everyday decisions.

Aidoc’s comprehensive foundation-model product may make future comparisons easier because one system can be tested across many acute findings. The company reports a large reduction in false alerts compared with single-condition systems, but independent studies still need to verify the size of that advantage.

Qure.ai has the cleanest independent win in a narrow head-to-head study. RapidAI, Aidoc and Viz.ai currently have stronger evidence that their products improve complex clinical workflows.

Which medical imaging AI startup offers hospitals the best economics?

Viz.ai currently has the strongest proven economic case in large American hospitals, while Qure.ai and AZmed look better suited to high-volume, lower-cost imaging.

Viz.ai built its early business around diseases where minutes can change treatment eligibility. Faster stroke alerts can help hospitals move more patients toward thrombectomy, avoid unnecessary transfers and reduce the time specialists spend coordinating care. The company also received one of the earliest dedicated Medicare add-on payments for medical AI.

Aidoc’s economic argument comes from spreading integration, security and monitoring costs across several applications on one platform. That becomes more attractive as hospitals move from one or two algorithms toward larger AI portfolios. Aidoc does not publish enough pricing data to calculate a clear payback period.

Qure.ai can screen large populations using equipment that already exists, then direct more expensive tests toward higher-risk patients. AZmed follows a similar high-volume logic in routine X-ray departments.

Exact prices remain private across most of the industry. Viz.ai has the best documented business case for complex hospital care, while Qure.ai and AZmed probably offer better economics for mass screening and routine radiography.

Which medical imaging AI startup has the hardest advantage to copy?

Viz.ai currently has the stickiest workflow advantage, while Aidoc may be building the stronger long-term platform.

Viz.ai’s software connects radiology, emergency teams, specialists, transfers and treatment decisions. Replacing it can disrupt several departments at once, which creates meaningful switching costs.

Aidoc’s advantage comes from breadth, data and deployment experience. Nearly 2,000 hospitals expose the company to many scanners, workflows and clinical environments. Its foundation-model strategy could also let Aidoc launch new applications faster.

Qure.ai owns a different moat. Relationships with ministries, public-health programs, nonprofit funders and clinics across more than 105 countries took years to build.

RapidAI benefits from deep clinical trust in stroke, where hospitals are reluctant to replace established tools without strong evidence.

Viz.ai has the stronger switching costs today. Aidoc has the clearer route toward a broader technology platform.

If you want more recent data on this point, please see our latest healthcare AI market report.

Which startup leads each part of the medical imaging AI market?

Medical imaging AI currently has several specialized leaders, even though Aidoc holds the strongest overall position.

RapidAI remains the benchmark for deep stroke imaging. Viz.ai is strongest at moving patients and information through a treatment pathway. Qure.ai leads global tuberculosis and public-health imaging. Harrison.ai is furthest ahead in comprehensive second-reading across chest X-rays and CT scans. AZmed has built a powerful position in routine radiography and fracture detection.

These boundaries are becoming less stable. Aidoc is entering report generation. Harrison.ai is building foundation models. Qure.ai is expanding further into the United States and ultrasound. RapidAI and Viz.ai are adding diseases beyond their original stroke products.

Medical imaging AI segment	Current leader	Why it leads today	Closest challenger
Broad enterprise radiology AI	Aidoc	Best mix of regulatory breadth, hospital depth and platform infrastructure	Viz.ai
Stroke image analysis	RapidAI	Deepest clinical evidence and full neurovascular imaging workflow	Viz.ai
Stroke and acute-care coordination	Viz.ai	Strongest specialist alerts, transfers and treatment orchestration	RapidAI
Global tuberculosis and public-health imaging	Qure.ai	Largest geographic footprint and millions of annual screenings	No close broad-platform rival
Comprehensive chest X-ray and CT second reading	Harrison.ai	Broad multi-finding products and advanced reporting research	Aidoc
Routine X-ray and fracture detection	AZmed	More than 2,500 facilities and growing independent validation	Harrison.ai
Emergency and incidental CT findings	Aidoc	Wider product breadth and much greater enterprise scale	Avicenna.AI
Configurable care pathways across specialties	Viz.ai	Hospitals can build workflows through Agent Studio	Aidoc

What could change the medical imaging AI ranking?

Viz.ai and Qure.ai have the clearest paths to challenging Aidoc, while Harrison.ai has the largest upside from a lower starting position.

Viz.ai could move first by maintaining profitability while Agent Studio becomes widely used across several clinical specialties.

Qure.ai could enter the top two by converting its 5,500-site footprint into deeper recurring revenue and larger American health-system contracts.

RapidAI could rise by proving that its recent expansion beyond stroke produces meaningful enterprise adoption.

Harrison.ai could jump several positions if its report-drafting model gains regulatory approval and performs reliably in hospitals.

Aidoc’s main challenge is economic. More than $500 million of funding raises expectations, and additional approvals will matter less than repeat usage, customer expansion and a credible path toward financial sustainability.

Which medical imaging AI startups are actually ahead?

Aidoc is currently the strongest medical imaging AI startup overall, followed closely by Viz.ai, with Qure.ai now moving ahead of RapidAI for third place.

Aidoc wins because it has the most complete combination of regulatory breadth, enterprise deployment, technical ambition, strategic customers and recent momentum. Its comprehensive foundation-model clearance and preliminary report-drafting program also give it a credible route beyond traditional single-condition triage.

Viz.ai remains a serious threat to that lead. It has a slightly larger reported hospital network, a healthcare business that is already profitable and a deeply embedded coordination layer. Aidoc currently covers more of the radiology stack, while Viz.ai has shown stronger evidence that its core business can support itself financially.

Qure.ai moves into third because the latest evidence is much stronger than it was even a few months ago. The company now reports more than 5,500 sites, 45 million lives reached and 26 FDA-cleared indications. Its reach is broader than RapidAI’s, and its recent regulatory expansion has reduced the gap with the leading American platforms.

RapidAI remains extremely strong and could reasonably rank third for a hospital focused mainly on stroke and neurovascular disease. It ranks fourth overall because the broader market is moving toward multi-disease platforms, comprehensive image interpretation and configurable enterprise workflows.

Harrison.ai holds fifth place. Its NHS expansion and foundation-model research give it more strategic upside than AZmed or Avicenna.AI, although its American approvals and visible commercial scale remain behind the top four.

The top two are separated by a relatively small gap. Aidoc leads today, but sustained profitable expansion from Viz.ai could reverse the order. Qure.ai and RapidAI form the next tier, with Qure.ai currently carrying more momentum and RapidAI retaining stronger specialist depth.

Rank	Startup	Why it holds this position
1	Aidoc	The strongest overall mix of regulatory breadth, enterprise adoption, platform depth, funding and current product momentum
2	Viz.ai	The best commercial evidence, with profitability, more than 2,000 hospitals and deeply embedded care-coordination workflows
3	Qure.ai	More than 5,500 sites, 26 FDA-cleared indications, rapid expansion and unmatched global public-health reach
4	RapidAI	The deepest clinical evidence and specialist maturity, especially in stroke, but slower visible expansion into a broad imaging platform
5	Harrison.ai	Major NHS adoption and leading foundation-model research, with commercialization and U.S. regulatory breadth still catching up
6	AZmed	More than 2,500 facilities, growing clinical evidence and exceptional capital efficiency in routine X-ray imaging
7	Avicenna.AI	Strong regulatory reach and focused CT products, offset by a smaller visible deployment and commercial footprint

If you want more recent data on this point, please see our latest healthcare AI market report.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.